Vigabatrin associated visual field loss: A clinical audit to study prevalence, drug history and effects of drug withdrawal

Eye

Volumn 16, Issue 5, 2002, Pages 567-571

  Newman, W D ^a   Tocher, K ^a   Acheson, J F ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Vigabatrin; Visual failure; Visual fields

Indexed keywords

ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CLOBAZAM; DIAZEPAM; GABAPENTIN; LAMOTRIGINE; PHENYTOIN; PREDNISOLONE; PRIMIDONE; TIAGABINE; TOPIRAMATE; VIGABATRIN;

ADOLESCENT; ADULT; AGED; ANAMNESIS; ARTICLE; COLOR VISION; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG WITHDRAWAL; EPILEPSY; FEMALE; FOLLOW UP; HEALTH CENTER; HEALTH SURVEY; HUMAN; KINETICS; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL AUDIT; NEUROLOGIC EXAMINATION; NEUROOPHTHALMOLOGY; PATHOGENESIS; PATIENT REFERRAL; PERIMETRY; PREVALENCE; QUANTITATIVE ANALYSIS; RETINA; VISUAL ACUITY; VISUAL FIELD DEFECT; VISUAL SYSTEM EXAMINATION; VISUAL SYSTEM FUNCTION;

EID: 0036740737     PISSN: 0950222X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.eye.6700168     Document Type: Article

References (20)

1. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997; 314: 180-181.
2. Wilson EA, Brodie MJ, Wong IC, Mawer GE, Sander JWAS, Blackwell N et al. Severe persistent visual field constriction associated with vigabatrin (multiple letters). BMJ 1997; 314: 1693-1695.
3. Harding HFA, Mackenzie R, Klistorner A. Severe persistent visual field constriction associated with Vigabatrin. BMJ 1998; 316: 232-233.
4. Beck RW, Brignell MG, Roubertie A, Bellet H, Echenne B, Krauss GL et al. Vigabatrin-associated retinal cone system dysfunction. Neurology 1998; 51: 1778-1778.
5. Daneshvar H, Racette L, Coupland SG, Kertes PJ, Guberman A, Zackon D. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 1999; 106: 1792-1798.
6. Lawden MC, Eke T, Degg C, Harding GF, Wild JM. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 1999; 67: 716-722.
7. Russell-Eggitt-IM, Mackey-DA, Taylor-DS, Timms-C, Walker-JW. Vigabatrin-associated visual field defects in children. Eye 2000; 14: 334-339.
8. Manuchehri K, Goodman S, Siviter L, Nightingale S. A controlled study of vigatrin and visual abnormalities. Br J Ophthalmol 2000; 84: 499-505.
9. Ruether K, Pung T, Kellner U, Schmitz B, Hartmann C, Seeliger M. Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin. Arch Ophthalmol 1998; 116: 817-819.
10. Kalviainen R, Nousiainen I, Mantyjarvi M et al. Vigabatrin, a GABAergic antiepiletic drug, causes concentric visual field defects. Neurology 1999; 53: 922-926.
11. Miller NR, Johnson MA, Paul SR, Girkin CA, Perry JD, Endres M, Krauss GL. Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. Neurology 1999; 53: 2082-2087.
12. Arndt CF, Derambure P, Defoort-Dhellemmes S, Hache JC. Outer retinal dysfunction in patients treated with vigabatrin. Neurology 1999; 52: 1201-1205.
13. Hardus P, Verduin WM, Postma G, Stilma JS, Berendschot TT, van Veelen CW. Long-term changes in the visual fields of patients with temporal lobe epilepsy using vigabtrin. Br J Ophthalmol 2000; 84: 788-790.
14. Coupland SG, Zackron DH, Leonard BC, Ross TM. Vigabatrin effect on inner retinal function. Ophthalmology 2001; 108: 1493-1496.
15. Harding GF, Wild JM, Robertson KA, Rietbrock S, Martinez C. Separating the retinal electrophysiologic effects of vigabatrin: treatment versus field loss. Neurology 2000; 55: 347-352.
16. Krakow K, Polizzi G, Riordan-Eva P, Holder G, MacLeod WN, Fish DR. Recovery of visual field constriction following discontinuation of vigabatrin. Seizure 2000; 9: 287-290.
17. Versino M, Viggiotti P. Reversibility of vigabatrin-induced visual field defect. Lancet 1999; 354: 486.
18. Johnson MA, Krauss GL, Miller NR, Medura M, Paul SR. Visual function loss from vigabatrin: effect of stopping the drug. Neurology 2000; 55: 40-45.
19. Diabetic Retinopathy Survey report 6 - Design, Methods and Baseline Results. Investig Ophthalmol Vis Sci 1981; 21: 149-209.
20. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 1998; 50: 614-618.